Breast cancer is the most common cancer in women, with a general upward trend in incidence. Basic and clinical breast cancer research has continued at a rapid pace, in the endeavor to understand the biology of the disease so as to improve management of patients. Besides traditional pathological indicators, expression of molecular markers in breast cancer has also been comprehensively investigated. This paper will focus on the prognostic utility of metallothioneins (MTs), a family of low molecular weight metal binding proteins encoded by at least 10 functional MT genes that are associated with cell proliferation in breast cancer. Evidence that MT is a potential prognostic biomarker for breast cancer is supported by many reports in the literature. Expression of the MT protein has been detected by immunohistochemistry in a significant portion of invasive ductal breast cancers. MT expression has also been well studied in association with traditional clinico-pathological parameters of breast cancers. Generally, higher MT expression in breast cancers is predictive of worse patient outcomes. The relationship of MT isoforms to histological grade, estrogen receptor (ER) status, and prognosis will also be discussed.
BreastedJH.The Edwin Smith Surgical Papyrus. Chicago: University of Chicago Press, pp403–406, 1990.
2.
WingoPA, RiesLA, RosenbergHM, MillerDS, EdwardsBK.Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer82:1197–1207, 1998.
3.
SeowA, KohWP, ChiaKS, LeeHP, ShanmugaratnamK.Cancer incidence in Singapore 1968–2002. Singapore: Singapore Cancer Registry Report No. 6, pp120–121, 2004.
4.
KelseyJL, Horn-RossPL. Breast cancer magnitude of the problem and descriptive epidemiology. Epidemiol Rev15:7–16, 1993.
5.
ParkinDM, WhelanSLFerlayJ, TeppoL, ThomasDB.Cancer Incidence in five continents. Lyon, France: International Agency for Research on Cancer (IARC) Press, IARC Scientific Publications, No. 155, Vol. VIII:pp603–605, 2003.
6.
GradisharWJ.The future of breast cancer the role of prognostic factors. Breast Cancer Res Treat89:S17–S26, 2005.
7.
FisherER, GregorioRM, FisherB, RedmondC, VelliosF, SommersSC.The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer36:1–85, 1975.
8.
WallgrenA, SilferswardC, EklundG.Prognostic factors in mammary carcinoma. Acta Radiol15:1–16, 1976.
9.
RosenPP.The pathological classification of human mammary carcinoma: past, present and future. Ann Clin Lab Sci9:144–156, 1979.
10.
PageDL, AndersonTJ, SakamotoG.Infiltrating carcinoma: major histological types. In: PageDL, AndersonTJ, Eds. Diagnostic histopathology of the breast. London, United Kingdom: WB Saunders, pp193–235, 1987.
11.
EllisIO, GaleaM, BroughtonN, LockerA, BlarneyRW, EistenCW.Pathological prognostic factors in breast cancer, II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology20:479–489, 1992.
12.
ElstonCW, EllisIO.Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology19:403–410, 1991.
13.
PereiraH, PinderSE, SibberingDM, GaleaMH, ElstonCW, BlameyRW, RobertsonJF, EllisIO.Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology27:219–226, 1995.
14.
BloomHJG, RichardsonWW.Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer11:359–377, 1957.
15.
MichaelsonJS, SilversteinM, WyattJ, WeberG, MooreR, HalpemE, KopensDB, HughesK.Predicting the survival of patients with breast carcinoma using tumor size. Cancer95:713–723, 2002.
16.
MichaelsonJS, SilversteinM, SgroiD, CheongiatsiatmoyJA, TaghianA, PowellS, HughesK, ComegnoA, TanabeKK, SmithB.The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer98:2133–2143, 2003.
17.
LindahlT, EngelG, AhlgrenJ, KlaarS, BjohleJ, LindmanH, AnderssonJ, von SchoultzE, BerghJ.Can axillary dissection be avoided by improved molecular biological diagnosis?Acta Oncol39:319–326, 2000.
18.
CioccaDR, ElledgeR.Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine13:1–10, 2000.
WoosterR, NeuhausenSL, MangionJ, QuirkY, FordD, CollinsN, NguyenK, SealS, TranT, AverillD, FieldsP, MarshallG, NarodS, LenoirGM, LynchH, FeunteunJ, DevileeP, ComelisseCJ, MenkoFH, DalyPA, OrmistonW, McMaiiusR, PyeC, LewisCM, Cannon-AlbrightLA, PetoJ, PonderBA, SkolnickMH, EastonDF, GoldgarDE, StrattonMR.Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science265:2088–2090, 1994.
21.
ArmstrongK, CalzoneK, StopferJ, FitzgeraldG, CoyneJ, WeberB.Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev9:1251–1254, 2000.
22.
NarodSA, BrunetJS, GhadirianP, RobsonM, HeimdalK, NeuhausenSL, Stoppa-LyonnetD, LermanC, PasiniB, de los RiosP, WeberB, LynchH.Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet356:1876–1881, 2000.
23.
OzbunMA, ButelJS.Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res66:71–141, 1995.
24.
BerghJ, NorbergT, SjogrenS, LindgrenA, HolmbergL.Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med1:1029–1034, 1995.
25.
GaspariniG, ToiM, VerderioP, RanieriG, DanteS, BonoldiE, BoracchiP, FanelliM, TominagaT.Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol12:1117–1125, 1998.
26.
PatersonMC, DietrichKD, DanylukJ, PatersonAH, LeesAW, JamilN, HansonJ, JenkinsH, KrauseBE, McBlainWA, BlamonDJ, FourneyRM.Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res51:556–567, 1991.
27.
SuganoK, UshiamaM, FukutomiT, TsudaH, KitohT, OhkuraH.Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer89:329–336, 2000.
28.
McNeilC.Herceptin in the adjuvant setting: phase III trials begin. J Natl Cancer Inst92:683–684, 2000.
29.
PupaSM, TagliabueE, MenardS, AnichiniA.HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J Cell Physiol205:10–18, 2005.
30.
MontraversF, YounsiN, RousseauC, PhilippeC, SeddikiM, UzanS, IzraelV, TalbotJN.Comparison of bone scanning and CA 15–3 serum concentration in the follow-up of breast cancer. Anticancer Res17:1683–1686, 1997.
31.
LumachiF, BrandesAA, BoccagniP, PolistinaF, FaviaG, D'AmicoDF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15–3. Anticancer Res19:4485–4489, 1999.
32.
LeonardiE, CristoforiA, CaffoO, Dalla PalmaP.Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of p53 product in the different ploidy classes. Anal Cell Pathol15:31–45, 1997.
33.
BillgrenAM, RutqvistLE, JohanssonH, HagerstromT, SkoogL.The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. Eur J Cancer36:1374–1380, 2000.
34.
BhatavdekarJM, PatelDD, ShahNG, VoraHH, SutharTP, ChikhlikarPR, GhoshN, TrivediTI.Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol7:305–311, 2000.
35.
ÁsgeirssonKS, JónassonJG, TryggvadóttirL, ÓlafsdóttirK, SigurgeirsdóttirJR, IngvarssonS, ÖgmundsdóttirHM. Altered expression of E-cadherin in breast cancer. Patterns, mechanisms and clinical significance. Eur J Cancer36:1098–1106, 2000.
36.
NakataB, OgawaY, IshikawaT, IkedaK, KatoY, NishinoH, HirakawaK.Serum CYFRA 21–1 is one of the most reliable tumor markers for breast carcinoma. Cancer89:1285–290, 2000.
37.
DuffyMJ.Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic biomarkers in breast cancer: from pilot to level 1 evidence studies. Clin Chem48:1194–1197, 2002.
38.
IoachimE, TsanouE, BriasoulisE, BatsisCh, KaravasilisV, CharchantiA, PavlidisN, AgnantisNJ.Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast12:111–119, 2003.
39.
HuangJ, TanPH, JayabaskarT, BayBH.Prognostic significance of glutathione-S-transferase-pi in invasive breast cancer. Mod Pathol16:558–565, 2003.
40.
UrruticoecheaA, SmithIE, DowsettM.Proliferation marker Ki-67 in early breast cancer. J Clin Oncol23:7212–7320, 2005.
41.
KeyomarsiK, TuckerSL, BuchholzTA, CallisterM, DingY, HortobagyiGN, BedrosianI, KnickerbockerC, ToyofukuW, LoweM, HerliczekTW, BacusSS.Cyclin E and survival in patients with breast cancer. N Engl J Med347:1566–1575, 2002.
42.
HuntK, KeyomarsiK.Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol15:319–326, 2005.
43.
MargoshesM, ValleeBL.A cadmium protein from equine kidney cortex. J Am Chem Soc79:4813–4814, 1957.
44.
KagiJHR, ValleeBL.Metallothionein: a cadmium- and zinc-containing protein from equine renal cortex. J Biol Chem235:3460–3465, 1960.
KagiJH, SchafferA.Biochemistry of metallothionein. Biochemistry27:8509–8515, 1988.
47.
BraunW, VasakM, RobbinsAH, StoutCD, WagnerG, KagiJH, WuthrichK.Comparison of the NMR solution structure and the X-ray crystal structure of rat metallothionein-2. Proc Natl Acad Sci U S A89:10124–10128, 1992.
48.
SchultzeP, WorgotterE, BraunW, WagnerG, VasakM, KagiJH, WuthrichK.Conformation of [Cd7]-metallothionein-2 from rat liver in aqueous solution determined by nuclear magnetic resonance spectroscopy. J Mol Biol203:251–268, 1988.
49.
BayBH, JinR.Jayasurya A. Analysis of metallothionein expression in human cancers. Acta Histochem Cytochem34:171–176, 2001.
50.
NagelWW, ValleeBL.Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci U S A92:579–583, 1995.
51.
JayasuryaA, BayBH, YapWM, TanNG, TanBKH. Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis21:1809–1812, 2000.
52.
LohrerH, RobsonT.Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis10:2279–2284, 1989.
53.
HussainS, SlikkerWJr, AliSF.Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in neuroprotection. Neurochem Int29:145–152, 1996.
54.
KellySL, BasuA, TeicherBA, HackerMP, HamerDH, LazoJS.Overexpression of metallothionein confers resistance to anticancer drugs. Science241:1813–1815, 1988.
55.
HeguyA, WestA, RichardsRI, KarinM.Structure and tissue-specific expression of the human metallothionein IB gene. Mol Cell Biol6:2149–2157, 1986.
56.
NarteyN, CherianMG, BanerjeeD.Immunohistochemical localization of metallothionein in human thyroid tumors. Am J Pathol129:177–182, 1987.
57.
FresnoM, WuW, RodriguezJM, NadjiM.Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol423:215–219, 1993.
58.
JinR, BayBH, ChowVT, TanPH, DheenT.Significance of metallothionein expression in breast myoepithelial cells. Cell Tissue Res303:221–226, 2001.
59.
BierB, Douglas-JonesA, TotschM, Dockhorn-DwomiczakB, BockerW, JasaniB, SchmidKW.Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat30:213–221, 1994.
60.
OyamaT, TakeH, HikinoT, linoY, NakajimaT.Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology53:112–117, 1996.
61.
GouldingH, JasaniB, PereiraH, ReidA, GaleaM, BellJA, EistonCW, RobertsonJF, BlarneyRW, NicholsonRA, SchmidKW, EllisIO.Metallothionein expression in human breast cancer. Br J Cancer72:968–972, 1995.
62.
JinR, ChowVT, TanPH, DheenST, DuanW, BayBH.Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis23:81–86, 2002.
63.
HaerslevT, JacobsenK, NedergaardL, ZedelerK.Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. Pathol Res Pract190:675–681, 1994.
64.
HaerslevT, JacobsenK, ZedelerK.The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS103:279–285, 1995.
65.
ZhangR, ZhangH, WeiH, LuoX.Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. J Environ Pathol Toxicol Oncol19:95–97, 2000.
66.
JinR, BayBH, ChowVT, TanPH.Metallothionein IF mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat66:265–272, 2001.
67.
SchmidKW, EllisIO, GeeJM, DarkeBM, LeesWE, KayJ, OyerA, StarkJM, HittmairA, OfnerD, MargreiterR, DaxenhichlerG, NicholsonRI, BierB, BockerW, JasaniBPresence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol422:153–159, 1993.
68.
Vazquez-RamirezFJ, Gonzalez-CamporaJJ, Hevia-AlvarezE, Fernandez-SantosJM, Rios-MartinJJ, Otal-SalaverriC, Gonzalez-CamporaR. P-glycoprotein, metallothionein and NM23 protein expressions in breast carcinoma. Pathol Res Pract196:553–559, 2000.
69.
JinR, HuangJ, TanPH, BayBH.Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res10:74–79, 2004.
70.
SurowiakP, MatkowskiR, MatemaV, GyorffyB, WojnaA, PudelkoM, DziegielP, KornafelJ, ZabelM.Elevated metallothionein (MT) expression in invasive ductal breast cancer predicts tamoxifen resistance. Histol Histopathol20:1037–1044, 2005.
71.
JinR, BayBH, ChowVT, TanPH, LinVC.Metallothionein IE mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br J Cancer83:319–323, 2000.
72.
SensMA, SomjiS, LammDL, GarrettSH, SlovinskyF, ToddJH, SensDA.Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol159:21–26, 2001.
73.
CherianMG, JayasuryaA, BayBH.Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res533:201–209, 2003.
74.
TheocharisSE, MargeliAP, KlijanienkoJT, KouraklisGP.Metallothionein expression in human neoplasia. Histopathology45:103–118, 2004.
